Day: February 22, 2022

Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO

National Cancer Institute Sponsored Phase 1/1b clinical study to test combination of epigenetic and immune-oncology therapies in solid tumors and...

error: Content is protected !!